The clinical evidence for postbiotics as microbial therapeutics

Simple item page
dc.contributor.authorMosca, Alexisen
dc.contributor.authorAbreu Y Abreu, Ana Teresaen
dc.contributor.authorGwee, Kok Annen
dc.contributor.authorIaniro, Gianlucaen
dc.contributor.authorTack, Janen
dc.contributor.authorNguyen, Thi Viet Haen
dc.contributor.authorHill, Colinen
dc.contributor.funderADAREen
dc.date.accessioned2024-04-11T10:31:38Z
dc.date.available2024-04-11T10:31:38Z
dc.date.issued2022en
dc.description.abstractAn optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the potential to manage these. However, their use in vulnerable people is linked to possible safety concerns and maintaining their viability is difficult. Interest in postbiotics is therefore increasing. Postbiotics contain inactivated microbial cells or cell components, thus are more stable and exert similar health benefits to probiotics. To review the evidence for the clinical benefits of postbiotics in highly prevalent conditions and consider future potential areas of benefit. There is growing evidence revealing the diverse clinical benefits of postbiotics in many prevalent conditions. Postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics. Establishing interaction mechanisms between postbiotics and commensal microorganisms will improve the understanding of potential clinical benefits and may lead to targeted postbiotic therapy.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid2117508en
dc.identifier.citationMosca, A., Abreu Y Abreu, A.T., Gwee, K.A., Ianiro, G., Tack, J., Nguyen, T.V.H. and Hill, C. (2022) ‘The clinical evidence for postbiotics as microbial therapeutics’, Gut Microbes, 14(1), 2117508 (14pp). doi: 10.1080/19490976.2022.2117508en
dc.identifier.doi10.1080/19490976.2022.2117508en
dc.identifier.eissn1949-0984en
dc.identifier.endpage14en
dc.identifier.issn1949-0976en
dc.identifier.issued1en
dc.identifier.journaltitleGut Microbesen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/15795
dc.identifier.volume14en
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.rights© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectMicrobiotaen
dc.subjectPostbioticsen
dc.subjectMicrobial therapeuticsen
dc.subjectClinical benefitsen
dc.subjectGastrointestinal disordersen
dc.subjectAllergyen
dc.subjectUpper respiratory tract infectionen
dc.subjectStressen
dc.subjectMetabolic syndromeen
dc.titleThe clinical evidence for postbiotics as microbial therapeuticsen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The clinical evidence for postbiotics as microbial therapeutics.pdf
Size:
1.29 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
APC Microbiome Ireland - Journal Articles